J&J: Inflationary Pressures ‘Here To Stay’ With Impact Likely Into 2023
Johnson & Johnson reported 3% sales growth in the second quarter, led by pharmaceuticals, which were positive financial results given persistent macroeconomic challenges and a currency headwind.
You may also be interested in...
The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line
Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.